Menu

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (12)

Company Market Cap Price
VRTX Vertex Pharmaceuticals Incorporated
JOURNAVX is a non-opioid pain management therapy, aligning with the non-opioid pain management investable theme.
$109.42B
$427.22
+0.11%
VTRS Viatris Inc.
Pipeline includes non-opioid pain management options (e.g., fast-acting meloxicam) as growth drivers.
$12.20B
$10.44
-0.24%
AXSM Axsome Therapeutics, Inc.
Symbravo's non-opioid analgesic profile supports Non-Opioid Pain Management as a broader category.
$7.46B
$150.59
+0.77%
ATRC AtriCure, Inc.
Pain-management devices (cryoSPHERE family, cryoXT) provide non-opioid analgesia, a key product category.
$1.80B
$37.80
+4.51%
LXRX Lexicon Pharmaceuticals, Inc.
Pilavapadin is a non-opioid pain management therapy in development for neuropathic pain, constituting a non-opioid analgesic product category.
$486.95M
$1.39
+3.36%
SCLX Scilex Holding Company
Core business focused on non-opioid pain management drugs and a pipeline of non-opioid therapies.
$156.57M
$21.61
-4.00%
ANIK Anika Therapeutics, Inc.
Non-opioid pain management solutions through HA injections address OA pain.
$142.45M
$9.94
+0.61%
ASRT Assertio Holdings, Inc.
INDOCIN, SPRIX, and CAMBIA represent non-opioid analgesics, supporting the Non-Opioid Pain Management theme.
$69.22M
$0.71
-1.57%
GRCE Grace Therapeutics, Inc.
GTx-101.00 is a non-narcotic topical analgesic in development for PHN, supporting the 'Non-Opioid Pain Management' theme.
$44.11M
$3.13
-1.72%
CPIX Cumberland Pharmaceuticals Inc.
Caldolor is a non-opioid IV analgesic, aligning CPIX with non-opioid pain management products.
$29.70M
$2.06
+3.78%
APUS Apimeds Pharmaceuticals US, Inc
Apitox functions as a non-opioid analgesic for pain management, aligning with the Non-Opioid Pain Management investable theme.
$28.67M
$2.04
-10.31%
MIRA MIRA Pharmaceuticals, Inc.
The company's pain therapies are non-opioid analgesics, placing them under 'Non-Opioid Pain Management'.
$26.51M
$1.43
+2.52%

Loading company comparison...

Loading research report...

The most compelling investment themes are the ones nobody is talking about yet.

Every Monday, get three under-the-radar themes with catalysts, data, and stocks poised to benefit.

Sign up now to receive them!

Also explore our analysis on 5,000+ stocks